DK0452457T3 - Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener - Google Patents

Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener

Info

Publication number
DK0452457T3
DK0452457T3 DK90916560.7T DK90916560T DK0452457T3 DK 0452457 T3 DK0452457 T3 DK 0452457T3 DK 90916560 T DK90916560 T DK 90916560T DK 0452457 T3 DK0452457 T3 DK 0452457T3
Authority
DK
Denmark
Prior art keywords
genetic material
cells
foreign genes
vivo removal
functional foreign
Prior art date
Application number
DK90916560.7T
Other languages
English (en)
Inventor
Kenneth L Brigham
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23712442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0452457(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Application granted granted Critical
Publication of DK0452457T3 publication Critical patent/DK0452457T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DK90916560.7T 1989-11-03 1990-10-18 Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener DK0452457T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43155289A 1989-11-03 1989-11-03

Publications (1)

Publication Number Publication Date
DK0452457T3 true DK0452457T3 (da) 1998-03-02

Family

ID=23712442

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90916560.7T DK0452457T3 (da) 1989-11-03 1990-10-18 Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener

Country Status (8)

Country Link
EP (2) EP0800830A3 (da)
JP (1) JP3056782B2 (da)
AT (1) ATE157012T1 (da)
AU (1) AU625013B2 (da)
CA (1) CA2044593C (da)
DE (1) DE69031305T2 (da)
DK (1) DK0452457T3 (da)
WO (1) WO1991006309A1 (da)

Families Citing this family (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585254A (en) * 1987-08-21 1996-12-17 University Of Colorado Foundation, Inc. Autonomous parvovirus gene delivery vehicles and expression vectors
US7238673B2 (en) 1989-03-31 2007-07-03 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5698531A (en) 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5643567A (en) * 1990-12-04 1997-07-01 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
WO1993012240A1 (en) 1991-12-17 1993-06-24 The Regents Of The University Of California Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr)
EP0646178A1 (en) * 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US6806084B1 (en) 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
US5821234A (en) * 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
WO1994005782A1 (en) * 1992-09-10 1994-03-17 Trustees Of Tufts College In vivo production of transgenic organ by introducing the transgene via lumen
US6015886A (en) * 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
CA2192342A1 (en) * 1994-07-15 1996-02-01 Ann L. Lee A method for large scale plasmid purification
US6197553B1 (en) 1994-07-15 2001-03-06 Merck & Co., Inc. Method for large scale plasmid purification
WO1996026742A1 (en) 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
US5885971A (en) 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
US6531455B1 (en) 1995-03-24 2003-03-11 The Regents Of The University Of California Delivery of polynucleotides by secretory gland expression
AR003122A1 (es) * 1995-05-19 1998-07-08 Merck & Co Inc Un proceso para aislacion y purificacion de plasmidos en fermentadores de gran escala y el adn aislado y purificado obtenido mediante dicho proceso.
KR100765687B1 (ko) 1995-08-29 2007-10-11 안제스에무지 가부시키가이샤 Ｈｇｆ 유전자를 함유하는 약제
IL115199A (en) 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition
JP2765814B2 (ja) * 1995-11-24 1998-06-18 コナミ株式会社 ビデオゲーム装置及びビデオゲームのプレイキャラクタ成長制御方法
US5783566A (en) * 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
US6225290B1 (en) 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7112338B2 (en) 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
CA2304983A1 (en) 1997-09-24 1999-04-01 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
JP2002500190A (ja) 1998-01-08 2002-01-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 海洋海綿から誘導されるキネシンモーターモジュレーター
US6410328B1 (en) 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
JP2002502831A (ja) * 1998-02-03 2002-01-29 イネックス ファーマシューティカルズ コーポレイション 癌の治療に用いる血清に対して安定なプラスミド脂質粒子の全身供与
CA2330824A1 (en) 1998-06-17 1999-12-23 Epimmune Inc. Hla binding peptides and their uses
JP2002538167A (ja) 1999-03-03 2002-11-12 バイオジェン インコーポレイテッド 脂質の代謝および貯蔵を調節する方法
US7396905B1 (en) 1999-05-21 2008-07-08 Mckeon Frank Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
EP1196609A2 (en) 1999-06-28 2002-04-17 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
KR20010093804A (ko) 1999-10-08 2001-10-29 무라야마 마사노리 심근증 유전자 치료
AU1661201A (en) 1999-11-18 2001-05-30 Epimmune, Inc. Heteroclitic analogs and related methods
CA2395839A1 (en) 1999-12-27 2001-07-05 The Regents Of The University Of California Gene therapy for congestive heart failure
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
CA2705366A1 (en) 2000-08-28 2002-03-07 Agensys, Inc. Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
WO2002077012A2 (en) 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreative peptides
US7541512B2 (en) 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
WO2002079447A2 (en) 2001-03-30 2002-10-10 Avigenics, Inc. Avian lysozyme promoter
US7176300B2 (en) 2001-03-30 2007-02-13 Avigenics, Inc. Avian lysozyme promoter
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
EP1900815B1 (en) 2001-07-12 2016-09-07 University of Massachusetts In vivo production of small interfering RNAs that mediate gene silencing
EP2345720A3 (en) 2001-07-12 2012-01-25 University of Massachusetts In vivo production of small interfering RNAs that mediate gene silencing
ES2537074T3 (es) 2001-09-06 2015-06-02 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
IL164079A0 (en) 2002-03-15 2005-12-18 Us Dept Veterans Affairs Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
CA2500715A1 (en) 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
JP2006508163A (ja) 2002-11-27 2006-03-09 アジェンシス， インコーポレイテッド 癌の処置および検出において有用な２４ｐ４ｃ１２と称される、核酸および対応タンパク質
EP1903056A3 (en) 2002-12-10 2008-05-07 Idm Pharma, Inc. HLA-A1, -A2 -A3, -A24, -B7, and -B44 binding peptides comprising tumor associated antigen epitopes, and compositions thereof
ATE521701T1 (de) 2003-01-22 2011-09-15 Univ Duke Verbesserte konstrukte zur expression lysosomaler polypeptide
CA2515699C (en) 2003-02-10 2015-01-27 Aya Jakobovits Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
RU2005141341A (ru) 2003-05-30 2006-06-10 Эйдженсис, Инк., Сша (Us) Полинуклеотид, родственный антигену стволовых клеток простаты (psca), и кодируемый им белок (пептид), гибридома и трансгенное животное для продуцирования антител, композиция для лечения, профилактики, диагностики и прогноза течения раковых заболеваний на их основе (варианты), способ определения их присутствия в исследуемом образце, способ генерации иммунного ответа, способ доставки цитотоксического или диагностического агента в клетку, способ ингибирования роста раковых клеток с их использованием
DK1633767T3 (da) 2003-06-02 2019-03-25 Univ Massachusetts Fremgangsmåder og sammensætninger til styring af virkning af rna-silencing
ES2357116T5 (es) 2003-06-02 2021-09-03 Univ Massachusetts Métodos y composiciones para mejorar la eficacia y especificad de FNAi
AU2004263830B2 (en) 2003-06-13 2008-12-18 Alnylam Pharmaceuticals, Inc. Double-stranded ribonucleic acid with increased effectiveness in an organism
EP1677735B1 (en) 2003-10-17 2014-07-23 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US7608699B2 (en) 2003-12-29 2009-10-27 Rockefeller University Synthetic nuclear localization signal derived from lentiviral integrase and methods of use thereof
JP2007521835A (ja) 2004-02-10 2007-08-09 トラスティーズ・オブ・ダートマウス・カレッジ ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法
EP2399924B1 (en) 2004-05-27 2015-01-28 Alnylam Pharmaceuticals, Inc. Nuclease resistant double-stranded ribonucleic acid
AU2005250370B2 (en) 2004-05-28 2010-04-01 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
NZ560320A (en) 2005-01-25 2011-02-25 Prolexys Pharmaceuticals Inc Quinoxaline derivatives as antitumor agents
CA2603093A1 (en) 2005-03-31 2006-10-05 Agensys, Inc. Antibodies and related molecules that bind to 161p2f10b proteins
UA95446C2 (ru) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1
CA2611002A1 (en) 2005-06-07 2006-12-14 The Rockefeller University Stimulation of pancreatic .beta. cell proliferation
WO2007005611A2 (en) 2005-06-30 2007-01-11 Whitehead Institute Progenitor cells and uses thereof
US7943134B2 (en) 2005-08-31 2011-05-17 Academia Sinica Compositions and methods for identifying response targets and treating flavivirus infection responses
WO2007051045A2 (en) 2005-10-28 2007-05-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of huntingtin gene
CA2626690A1 (en) 2005-11-09 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor v leiden mutant gene
WO2009051846A2 (en) 2007-10-18 2009-04-23 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
SI2671954T1 (sl) 2006-01-20 2018-11-30 Cell Signaling Technology, Inc. Translokacija in mutantna ROS kinaza v človeškem ne-drobnoceličnem karcinomu pljuč
EP2450437B1 (en) 2006-04-14 2017-05-17 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
EP1920775B1 (en) 2006-10-10 2012-12-19 Gunther Prof. Dr. Hartmann 5'Triphosphate oligonucleotide induces anti-viral response
EP3342415B1 (en) 2006-08-08 2022-01-26 Rheinische Friedrich-Wilhelms-Universität Bonn Structure and use of 5' phosphate oligonucleotides
US8664364B2 (en) 2007-01-24 2014-03-04 Carnegie Mellon University Optical biosensors
CN101678082B (zh) 2007-03-26 2013-06-19 再生医药有限公司 使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法
AU2008319053B2 (en) 2007-11-01 2012-04-26 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
JP2011502484A (ja) 2007-11-01 2011-01-27 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｈｌａ−ｄｒ結合性ペプチドおよびそれらの使用
EP2297323A1 (en) 2008-05-21 2011-03-23 Hartmann, Gunther 5' triphosphate oligonucleotide with blunt end and uses thereof
EP2342616A2 (en) 2008-09-23 2011-07-13 Alnylam Pharmaceuticals Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
AU2010211133A1 (en) 2009-02-03 2011-07-21 F. Hoffmann-La Roche Ag Compositions and methods for inhibiting expression of PTP1B genes
AU2010213578B2 (en) 2009-02-12 2015-01-29 Cell Signaling Technology, Inc. Mutant ROS expression in human cancer
WO2010096388A2 (en) 2009-02-18 2010-08-26 Carnegie Mellon University Quenched dendrimeric dyes for bright detection
WO2011005496A2 (en) 2009-06-22 2011-01-13 Massachusetts Eye & Ear Infirmary Islet1 (isl1) and hearing loss
US20110300205A1 (en) 2009-07-06 2011-12-08 Novartis Ag Self replicating rna molecules and uses thereof
EP4218799A1 (en) 2009-07-15 2023-08-02 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
US20110112176A1 (en) 2009-11-09 2011-05-12 John Frederick Boylan Compositions and methods for inhibiting expression of kif10 genes
WO2011064751A1 (en) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
EP2504439B1 (en) 2009-11-27 2016-03-02 BASF Plant Science Company GmbH Optimized endonucleases and uses thereof
US10316304B2 (en) 2009-11-27 2019-06-11 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
US20110152349A1 (en) 2009-12-18 2011-06-23 Anke Geick Compositions and methods for inhibiting expression of il-18 genes
CN108404123A (zh) 2010-01-15 2018-08-17 康奈尔大学 降低细胞内蛋白质水平的方法
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
US20110196016A1 (en) 2010-02-05 2011-08-11 Anke Geick Compositions and Methods for Inhibiting Expression of IKK2 Genes
BR112012029066A2 (pt) 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
EP2577309B1 (en) 2010-05-25 2016-11-23 Carnegie Mellon University Targeted probes of cellular physiology
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
JP2013544504A (ja) 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
EP2630240A1 (en) 2010-10-18 2013-08-28 Arrowhead Research Corporation Compositions and methods for inhibiting expression of rrm2 genes
CA2823194A1 (en) 2010-12-27 2012-07-05 Brown University Therapeutic and diagnostic methods involving biglycan and utrophin
AU2012211278B2 (en) 2011-01-26 2016-11-10 Glaxosmithkline Biologicals Sa RSV immunization regimen
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
DK2707385T3 (da) 2011-05-13 2017-11-20 Glaxosmithkline Biologicals Sa RSV-F-præfusionsantigener
HRP20181564T1 (hr) 2011-06-30 2018-11-30 Arrowhead Pharmaceuticals, Inc. Pripravci i postupci za inhibiciju ekspresije gena virusa hepatitisa b
AU2012312520A1 (en) 2011-09-20 2014-05-08 The University Of North Carolina At Chapel Hill Regulation of sodium channels by PLUNC proteins
BR112014008694A2 (pt) 2011-10-11 2017-06-20 Novartis Ag moléculas de ácido nucleico policistrônico recombinante
WO2013054199A2 (en) 2011-10-12 2013-04-18 Novartis Ag Cmv antigens and uses thereof
EP2785370B1 (en) 2011-12-02 2021-07-21 Rhode Island Hospital Vaccine for falciparum malaria
EP2612918A1 (en) 2012-01-06 2013-07-10 BASF Plant Science Company GmbH In planta recombination
DK2838998T3 (da) 2012-04-18 2018-01-15 Cell Signaling Technology Inc Egfr og ros1 i kræft
EP2877214B1 (en) 2012-07-26 2019-04-24 Joslin Diabetes Center, Inc. Predicting diabetic complications
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
WO2014128257A1 (en) 2013-02-22 2014-08-28 Sanofi Serpins: methods of therapeutic beta-cell regeneration and function
EP2851086A1 (en) 2013-09-20 2015-03-25 Sanofi Serpins: methods of therapeutic ß-cell regeneration and function
EP2769732A1 (en) 2013-02-22 2014-08-27 Sanofi Serpins: methods of therapeutic beta-cell regeneration and function
JP6576904B2 (ja) 2013-04-04 2019-09-18 トラスティーズ・オブ・ダートマス・カレッジ ＨＩＶ−１プロウイルスＤＮＡのｉｎｖｉｖｏ切除のための組成物及び方法
CN118750591A (zh) 2013-04-07 2024-10-11 博德研究所 用于个性化瘤形成疫苗的组合物和方法
EP3052107B1 (en) 2013-10-04 2018-05-02 Novartis AG Organic compounds to treat hepatitis b virus
JP6694811B2 (ja) 2013-10-04 2020-05-20 ノバルティス アーゲー ＲＮＡ干渉に使用するためのＲＮＡｉ剤用の３’末端キャップ
EP3052627B1 (en) 2013-10-04 2018-08-22 Novartis AG Novel formats for organic compounds for use in rna interference
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
SG11201607772WA (en) 2014-03-31 2016-10-28 Debiopharm Int Sa Fgfr fusions
EP4372091A3 (en) 2014-12-12 2024-07-31 Tod M. Woolf Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
PL3265568T3 (pl) 2015-03-06 2020-11-30 Massachusetts Eye & Ear Infirmary Terapie augmentacji genów w przypadku wrodzonego zwyrodnienia siatkówki spowodowanego mutacjami genu prpf31
EP3294332A4 (en) 2015-05-14 2018-12-26 Joslin Diabetes Center, Inc. Retinol-binding protein 3 (rbp3) as a protective factor in non-diabetic retinal degeneration
TW202523682A (zh) 2015-05-20 2025-06-16 美商博德研究所有限公司 共有之gata3相關之腫瘤特異性新抗原
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
KR20180038465A (ko) 2015-08-07 2018-04-16 애로우헤드 파마슈티컬스 인코포레이티드 Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
WO2017066796A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
WO2017066712A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
AU2016355178B9 (en) 2015-11-19 2019-05-30 Massachusetts Institute Of Technology Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
EP3405576A4 (en) 2016-01-19 2019-09-18 The University of North Carolina at Chapel Hill METHOD AND COMPOSITIONS WITH RNA INTERFERENCE FOR KRAS INHIBITION
AU2017222450A1 (en) 2016-02-22 2018-09-27 The University Of North Carolina At Chapel Hill Peptide inhibitors of calcium channels
FI3436048T3 (fi) 2016-03-31 2025-09-15 Biontech Us Inc Neoantigeeneja ja niiden käyttömenetelmiä
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
JP6872560B2 (ja) 2016-05-06 2021-05-19 エム． ウルフ、トッド プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US12303561B2 (en) 2017-04-03 2025-05-20 Biontech Us Inc. Protein antigens and uses thereof
EP3609577B1 (en) 2017-04-14 2024-09-11 University of Massachusetts Brown fat-selective adipokines
MX2019013259A (es) 2017-05-08 2020-01-13 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus.
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
CN110720127A (zh) 2017-06-09 2020-01-21 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
KR20260039788A (ko) 2017-10-10 2026-03-20 시애틀 프로젝트 코포레이션 핫스팟을 이용한 신생항원 동정
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
EP3735271A4 (en) 2018-01-04 2022-06-15 Iconic Therapeutics, Inc. ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS
US12582702B2 (en) 2018-05-11 2026-03-24 University Of Massachusetts Methods for improving leptin sensitivity for the treatment of obesity and diabetes
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
CA3143679A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
KR20220042116A (ko) 2019-06-18 2022-04-04 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 B형 간염 바이러스(HBV) 백신 및 HBV-타케팅 RNAi의 조합
EP4025244A1 (en) 2019-09-02 2022-07-13 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
WO2021078910A1 (en) 2019-10-22 2021-04-29 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
CN115427568A (zh) 2020-02-12 2022-12-02 麻省眼耳科医院 Rp1相关视网膜变性的基于单倍型的治疗
WO2021228999A1 (en) 2020-05-12 2021-11-18 Institut Curie Neoantigenic epitopes associated with sf3b1 mutations
KR20230046313A (ko) 2020-08-06 2023-04-05 그릿스톤 바이오, 인코포레이티드 다중에피토프 백신 카세트
EP4229205B1 (en) 2020-10-15 2025-05-14 F. Hoffmann-La Roche AG Nucleic acid constructs for va rna transcription
WO2022079082A1 (en) 2020-10-15 2022-04-21 F. Hoffmann-La Roche Ag Nucleic acid constructs for simultaneous gene activation
MX2023007003A (es) 2020-12-14 2023-08-18 Biontech Us Inc Antigenos especificos de tejidos para la inmunoterapia del cancer.
WO2022155500A1 (en) 2021-01-14 2022-07-21 Senti Biosciences, Inc. Secretable payload regulation
US20250041412A1 (en) 2021-03-11 2025-02-06 Institut Curie Transmembrane neoantigenic peptides
EP4304632A2 (en) 2021-03-11 2024-01-17 Mnemo Therapeutics Tumor neoantigenic peptides
JP2024511119A (ja) 2021-03-22 2024-03-12 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 修飾されたペプチド模倣薬および使用方法
JP2025510795A (ja) 2022-03-24 2025-04-15 アンスティテュ・クリー 神経膠芽腫における腫瘍転位因子由来のネオ抗原ペプチドを標的化する免疫療法
US12084703B2 (en) 2022-05-12 2024-09-10 SunVax mRNA Therapeutics Inc. Synthetic self-amplifying mRNA molecules with secretion antigen and immunomodulator
KR20250021330A (ko) 2022-05-25 2025-02-12 비온테크 에스이 원숭이두창 항원 전달을 위한 rna 조성물 및 관련 방법
CN114958912B (zh) * 2022-05-30 2023-11-10 新乡医学院 一种hek293细胞瞬时表达转染用试剂和瞬时表达系统转染方法
CN121772938A (zh) 2023-08-03 2026-03-31 百欧恩泰欧洲股份公司 用于递送单纯疱疹病毒抗原的药物组合物及相关方法
WO2025064470A1 (en) 2023-09-19 2025-03-27 Regeneron Pharmaceuticals, Inc. Viral peptides and uses thereof
WO2025088117A1 (en) 2023-10-25 2025-05-01 Rheinische Friedrich-Wilhelms-Universität Bonn Ribonucleic acid construct capable of inducing an immune response, as well as pharmaceutical composition and kit comprising same
WO2025136809A2 (en) 2023-12-19 2025-06-26 Regeneron Pharmaceuticals, Inc. Foxp3 peptides and uses thereof
WO2025158069A1 (en) 2024-01-25 2025-07-31 Rheinische Friedrich-Wilhelms-Universität Bonn CONSTRUCT COMPRISING mRNA-STRAND AND RETINOIC ACID-INDUCIBLE GENE I (RIG-I)-LIGAND(S), PHARMACEUTICAL COMPOSITION AND KIT COMPRISING THE SAME
WO2025178991A1 (en) 2024-02-21 2025-08-28 Regeneron Pharmaceuticals, Inc. Splicing factor gene mutation-associated neoantigenic peptides and uses thereof
WO2025189168A1 (en) 2024-03-08 2025-09-12 SunVax mRNA Therapeutics Inc. Methods for cascade amplifications of therapeutic payloads (catp) & compositions for cancer immunotherapies and gene therapy
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026047025A1 (en) 2024-08-27 2026-03-05 Rheinische Friedrich-Wilhelms-Universität Bonn Photocontrollable conjugate, pharmaceutical composition and kit comprising the same, and uses thereof
EP4702988A1 (en) 2024-08-28 2026-03-04 Biotechnology Assets S.A. Combination product for the treatment of leishmaniasis
WO2026062222A1 (en) 2024-09-20 2026-03-26 Institut Curie Novel protein isoforms and uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2942780A1 (de) * 1979-10-23 1981-05-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Eukaryotische zellen, eukaryotische protoplasten und vielzellige eukaryotische lebende organismen mit einem gehalt an durch lipidvesikel eingebrachter dna, verfahren zu ihrer herstellung von gen-produkten, zur immunisierung und zur behebung genetisch bedingter defekte
US4579821A (en) * 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4789633A (en) * 1984-04-19 1988-12-06 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
NZ219392A (en) * 1986-02-28 1989-05-29 Smithkline Beckman Corp Production of an immortalised primary cell line
WO1990001543A1 (fr) * 1988-07-29 1990-02-22 Intracel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates

Also Published As

Publication number Publication date
AU625013B2 (en) 1992-06-25
ATE157012T1 (de) 1997-09-15
EP0800830A2 (en) 1997-10-15
CA2044593A1 (en) 1991-05-04
JP3056782B2 (ja) 2000-06-26
AU6645690A (en) 1991-05-31
DE69031305D1 (de) 1997-09-25
DE69031305T2 (de) 1998-03-26
EP0452457B1 (en) 1997-08-20
JPH04502772A (ja) 1992-05-21
CA2044593C (en) 2004-04-20
WO1991006309A1 (en) 1991-05-16
EP0452457A1 (en) 1991-10-23
EP0452457A4 (en) 1993-02-17
EP0800830A3 (en) 1999-03-17

Similar Documents

Publication Publication Date Title
DK0452457T3 (da) Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener
ES2149818T3 (es) Sistema y metodo para el transplante de celulas.
DE69032809D1 (de) Herstellung von Proteinen mittels homologer Rekombination
FI94265C (fi) Menetelmä lignoselluloosamateriaalin valkaisemiseksi happi- ja entsyymikäsittelyllä
DE68907153D1 (de) Zellkultur-geraet.
FI820075L (fi) Rekombination-dna-medel och foerfarande
DE3687705D1 (de) Molekulare zuechtung.
IL68366A (en) Process for expressing a gene encoding a protein comprising the enzymatic portion of human urokinase in a microorganism or cell culture
FI893542A0 (fi) Entsyymielektrodit ja menetelmä niiden valmistamiseksi
EP0835099A4 (en) METHOD FOR CELL TRANSFECTION WITH LIPOSOMAL-ENCLOSED NUCLEIC ACIDS
ES2115662T3 (es) Modificacion genetica de celulas endoteliales.
DE69803065D1 (de) Zellkulturmatrix und biologisch abbaubare dreidimensionale matrix auf hyaluronsäurederivatbasis
FI972821L (fi) Geneettisesti ohjatun solukuoleman geenit ja proteiinit
FI950409L (fi) Yhdistelmä soluja, DNA-rakenteita, vektoreita ja menetelmiä fytaattia hajoittavien entsyymien ilmentämiseksi toivotuissa suhteissa
HUT58798A (en) Process for producing growth factor of parenchimic hepatic celles, the gen for coding this and transformants for producing this factor
ATE120486T1 (de) Vektor zur integrationsstellenunabhängigen genexpression in säugetier-wirtszellen.
ATE118547T1 (de) Produktion von kallikrein.
ATE243741T1 (de) Zufuhr von genprodukten mittels mesangium-zellen
FI913266A7 (fi) Menetelmä ulkosyntyisen DNA:n viemiseksi eläinten somaattisten ja itur adan solujen sisään
NZ234283A (en) Gas ejection of non cellular biological material into cells
HUP9800520A2 (hu) Génexpresszió emlős sejtekben
IL95330A0 (en) Expression of a functional insect specific toxin gene in mammalian cells
ES2058274T3 (es) Un metodo para expresar un producto genico heterologo no bacteriano.
Papaphilis Insulin responsiveness of a mouse mammary adenocarcinoma culture in the expression of two proliferation-derived cytoplasmic proteins
FI884845A7 (fi) Menetelmä geenin monistamiseksi tarkoituksena lisätä proteiinin tuotantoa viljellyissa eläinsoluissa